• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dosing issues with non-vitamin  K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. Arch Cardiovasc Dis. 2017 Oct 02;: Authors: Dillinger JG, Aleil B, Cheggour S, Benhamou Y, Béjot Y, Marechaux S, Delluc A, Bertoletti L, Lellouche N Abstract Non-vitamin K antagonist oral anticoagulants (NOACs) - dabigatran, rivaroxaban, apixaban and edoxaban - are well established in terms of preventing stroke or systemic embolism in patients with non-valvular atrial fibrillation and high thromboembolism risk. When prescribed incorrectly...
Source: Archives of Cardiovascular Diseases - October 2, 2017 Category: Cardiology Authors: Dillinger JG, Aleil B, Cheggour S, Benhamou Y, Béjot Y, Marechaux S, Delluc A, Bertoletti L, Lellouche N Tags: Arch Cardiovasc Dis Source Type: research

Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
CONCLUSIONS: At the beginning of NOAC prescriptions, European doctors tended to switch from VKAs to NOACs those patients at lower risk than "non-switchers". Complaints about bruising or bleeding, dissatisfaction with treatment, mobility problems and anxiety/depression traits appear to be related to - and may have influenced - the choice to switch from a VKA to a NOAC. PMID: 28942115 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - September 20, 2017 Category: Cardiology Authors: De Caterina R, Brüggenjürgen B, Darius H, Köhler S, Lucerna M, Pecen L, Renda G, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P Tags: Arch Cardiovasc Dis Source Type: research

Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
CONCLUSIONS: LAAC using an ACP device followed by single antiplatelet therapy could be a reasonable alternative for stroke prevention. PMID: 28065447 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - January 2, 2017 Category: Cardiology Authors: Jalal Z, Dinet ML, Combes N, Pillois X, Renou P, Sibon I, Iriart X, Thambo JB Tags: Arch Cardiovasc Dis Source Type: research

Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
CONCLUSION: In this prospective registry, there were no significant differences in the rates of in-hospital MACE or major bleeding after prehospital initiation of UFH, enoxaparin or bivalirudin in patients treated by primary PCI for STEMI. PMID: 27818120 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - November 2, 2016 Category: Cardiology Authors: Auffret V, Leurent G, Boulmier D, Bedossa M, Zabalawi A, Hacot JP, Coudert I, Filippi E, Castellant P, Rialan A, Rouault G, Druelles P, Boulanger B, Treuil J, Avez B, Le Guellec M, Gilard M, Le Breton H Tags: Arch Cardiovasc Dis Source Type: research

Initial experience with the WATCHMAN ™ left atrial appendage system for stroke prevention in atrial fibrillation: A single-centre registry.
CONCLUSION: When performed by an operator trained in the procedure, WM implantation appears to be safe and effective. This procedure may be considered in patients at high-risk of stroke who are ineligible for long-term OAC. PMID: 27594651 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - August 31, 2016 Category: Cardiology Authors: Bonnet G, Salaun E, Pankert M, Cuisset T, Bonnet JL Tags: Arch Cardiovasc Dis Source Type: research

Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
CONCLUSION: The rate of major bleeding, particularly out-of-hospital bleeding, in patients treated with prasugrel is low within 1 year after a STEMI. Accurate selection of patient candidates for prasugrel is likely to have reduced the risk of bleeding. PMID: 26514325 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - October 26, 2015 Category: Cardiology Authors: Bacquelin R, Oger E, Filippi E, Hacot JP, Auffret V, Le Guellec M, Coudert I, Castellant P, Moquet B, Druelles P, Rialan A, Rouault G, Boulanger B, Treuil J, Leurent G, Bedossa M, Boulmier D, Avez B, Gilard M, Le Breton H Tags: Arch Cardiovasc Dis Source Type: research

Transradial versus transfemoral approach for percutaneous coronary intervention in cardiogenic shock: A radial-first centre experience and meta-analysis of published studies.
CONCLUSION: The transradial approach in the setting of PCI for ischaemic CS is associated with a dramatic reduction in mortality, ischaemic and bleeding events, and should be preferred to the transfemoral approach in radial expert centres. PMID: 26365478 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - September 10, 2015 Category: Cardiology Authors: Roule V, Lemaitre A, Sabatier R, Lognoné T, Dahdouh Z, Berger L, Milliez P, Grollier G, Montalescot G, Beygui F Tags: Arch Cardiovasc Dis Source Type: research

Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: Insights from the International RealiseAF Survey.
CONCLUSION: There is substantial deviation from international guidelines in antithrombotic use for AF in routine clinical practice, with overuse and underuse of antithrombotics in about 50% of the cases and important geographical differences. These findings emphasize the need for improved medical education worldwide and a better understanding of geographical disparities in the implementation of guidelines. PMID: 24556189 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - February 17, 2014 Category: Cardiology Authors: Gamra H, Murin J, Chiang CE, Naditch-Brûlé L, Brette S, Steg PG, RealiseAF investigators Tags: Arch Cardiovasc Dis Source Type: research

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects.
CONCLUSION: CYP2C19 polymorphism is significantly associated with risk of adverse clinical events in clopidogrel-treated patients. PMID: 24080325 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - September 27, 2013 Category: Cardiology Authors: Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W Tags: Arch Cardiovasc Dis Source Type: research

Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people.
The objectives of AF treatment in the elderly are to prevent AF complications, particularly stroke, and improve quality of life. Specific precautions for treatment must be taken because of the co-morbidities and age-related changes in pharmacokinetics or pharmacodynamics. Preventing AF complications relies mainly on anticoagulant therapy. Anticoagulants are recommended in patients with AF aged 75 years or above after assessing the bleeding risk using the HEMORR2HAGES or HAS-BLED scores. Novel oral anticoagulants (NOACs) are promising treatments, especially due to a lower risk of intracerebral haemorrhage. However, their pr...
Source: Archives of Cardiovascular Diseases - May 1, 2013 Category: Cardiology Authors: Hanon O, Assayag P, Belmin J, Collet JP, Emeriau JP, Fauchier L, Forette F, Friocourt P, Gentric A, Leclercq C, Komajda M, Le Heuzey JY Tags: Arch Cardiovasc Dis Source Type: research

Pages: 1  2  3